Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS).

Björn Ställberg, Christer Janson, Gunnar Johansson, Kjell Larsson, Georgios Stratelis, Gunilla Telg, Karin H Lisspers
{"title":"Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS).","authors":"Björn Ställberg, Christer Janson, Gunnar Johansson, Kjell Larsson, Georgios Stratelis, Gunilla Telg, Karin H Lisspers","doi":"10.4104/pcrj.2013.00106","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is one of the most common causes of mortality and a major contributor to morbidity. Longitudinal clinical practice data yielding information on the characteristics of the disease, its natural course, and management are limited.</p><p><strong>Aims: </strong>To investigate and describe the COPD population from a nationwide perspective during an 11-year period (1999-2009) with a focus on management, co-morbidity, and mortality.</p><p><strong>Methods: </strong>This observational retrospective epidemiological study linked electronic medical records data from patients with COPD in primary care to mandatory Swedish hospital, drug and Cause of Death registry data from 1999 to 2009 (PATHOS).</p><p><strong>Results: </strong>A total of 21,361 patients with a COPD diagnosis were included (mean age 68.0 years, 53% females). The proportion of patients diagnosed in primary care increased from 59% in 1999 to 81% in 2009 and the mean age at diagnosis decreased from 73 to 66 years. The number of exacerbations decreased from 3.0 to 1.3 and COPD-related hospitalisations decreased from 1.02 to 0.20 per patient per year. Prescriptions of long-acting muscarinic antagonists and fixed combinations of inhaled corticosteroid/long-acting β2-agonist inhalers increased from 0% to 36% and 37%, respectively. The most common co-morbidities were hypertension, heart failure, ischaemic heart disease, and diabetes. Overall life expectancy was 8.3±6.8 years shorter in patients with COPD than in the general population, and all- cause mortality was 3.5 times higher.</p><p><strong>Conclusions: </strong>Management of COPD in Sweden has improved during the 11-year study period. Despite this, patients with COPD have a substantially reduced life expectancy than the general population.</p>","PeriodicalId":48998,"journal":{"name":"Primary Care Respiratory Journal","volume":"23 1","pages":"38-45"},"PeriodicalIF":0.0000,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443109/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Primary Care Respiratory Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4104/pcrj.2013.00106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is one of the most common causes of mortality and a major contributor to morbidity. Longitudinal clinical practice data yielding information on the characteristics of the disease, its natural course, and management are limited.

Aims: To investigate and describe the COPD population from a nationwide perspective during an 11-year period (1999-2009) with a focus on management, co-morbidity, and mortality.

Methods: This observational retrospective epidemiological study linked electronic medical records data from patients with COPD in primary care to mandatory Swedish hospital, drug and Cause of Death registry data from 1999 to 2009 (PATHOS).

Results: A total of 21,361 patients with a COPD diagnosis were included (mean age 68.0 years, 53% females). The proportion of patients diagnosed in primary care increased from 59% in 1999 to 81% in 2009 and the mean age at diagnosis decreased from 73 to 66 years. The number of exacerbations decreased from 3.0 to 1.3 and COPD-related hospitalisations decreased from 1.02 to 0.20 per patient per year. Prescriptions of long-acting muscarinic antagonists and fixed combinations of inhaled corticosteroid/long-acting β2-agonist inhalers increased from 0% to 36% and 37%, respectively. The most common co-morbidities were hypertension, heart failure, ischaemic heart disease, and diabetes. Overall life expectancy was 8.3±6.8 years shorter in patients with COPD than in the general population, and all- cause mortality was 3.5 times higher.

Conclusions: Management of COPD in Sweden has improved during the 11-year study period. Despite this, patients with COPD have a substantially reduced life expectancy than the general population.

Abstract Image

Abstract Image

Abstract Image

11 年间慢性阻塞性肺病的管理、发病率和死亡率:瑞典的一项观察性回顾流行病学登记研究 (PATHOS)。
背景:慢性阻塞性肺疾病(COPD)是导致死亡的最常见原因之一,也是导致发病的主要因素。目的:从全国角度调查和描述 11 年间(1999-2009 年)慢性阻塞性肺疾病患者的情况,重点关注管理、共病和死亡率:这项观察性回顾流行病学研究将基层医疗机构中慢性阻塞性肺病患者的电子病历数据与1999年至2009年瑞典强制性医院、药物和死因登记数据(PATHOS)联系起来:研究共纳入了 21,361 名慢性阻塞性肺病患者(平均年龄 68.0 岁,53% 为女性)。在初级医疗机构确诊的患者比例从 1999 年的 59% 上升至 2009 年的 81%,确诊时的平均年龄从 73 岁降至 66 岁。病情恶化的次数从 3.0 次减少到 1.3 次,与慢性阻塞性肺病相关的住院次数从每年每名患者 1.02 次减少到 0.20 次。长效毒蕈碱拮抗剂和吸入式皮质类固醇/长效β2-受体激动剂固定组合吸入剂的处方率分别从0%增至36%和37%。最常见的并发症是高血压、心力衰竭、缺血性心脏病和糖尿病。慢性阻塞性肺病患者的总预期寿命比普通人群短8.3±6.8年,全因死亡率是普通人群的3.5倍:结论:在11年的研究期间,瑞典对慢性阻塞性肺病的管理有所改善。尽管如此,慢性阻塞性肺病患者的预期寿命仍大大低于普通人群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Primary Care Respiratory Journal
Primary Care Respiratory Journal PRIMARY HEALTH CARE-RESPIRATORY SYSTEM
自引率
0.00%
发文量
0
审稿时长
6-12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信